Stereotaxis Acquires Robocath for Up to $45 Million
Stereotaxis has agreed to acquire Robocath for up to $45 million to expand its robotic platform for endovascular procedures. The acquisition includes $20 million upfront and up to $25 million in milestone payments, with completion expected in mid-2026. Robocath's R-One+ system is the only commercially available robotic solution for coronary interventions in Europe.
Tickers: $STXS
Topics: acquisition endovascular procedures medical technology robotic solutions